Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Multiple dietary supplements do not affect metabolic and cardiovascular health
Andreea Soare
Washington University School of Medicine in St. Louis

Edward P. Weiss
Washington University School of Medicine in St. Louis

John O. Holloszy
Washington University School of Medicine in St. Louis

Luigi Fontana
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Soare, Andreea; Weiss, Edward P.; Holloszy, John O.; and Fontana, Luigi, ,"Multiple dietary supplements do
not affect metabolic and cardio-vascular health." Aging. 6,2. 149-157. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2607

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

AGING, February 2014, Vol. 6, No 2

www.impactaging.com

Research Paper

Multiple dietary supplements do not affect metabolic and cardio‐
vascular health
Andreea Soare1,2*, Edward P. Weiss1,3*, John O. Holloszy1, and Luigi Fontana1,4,5
1

Division of Geriatrics and Nutritional Sciences, Department of Medicine, Washington University School of
Medicine, St. Louis, MO 63130, USA
2
Department of Endocrinology and Diabetes, University Campus Bio‐Medico, Rome, Italy
3
Department of Nutrition and Dietetics, St. Louis University, St. Louis, MO 63130, USA
4
Department of Medicine, Salerno University School of Medicine, Salerno, Italy
5
CEINGE Biotecnologie Avanzate, Napoli, Italy
* These authors contributed equally to this research
Key words: supplements, endothelial function, arterial stiffness, inflammation, oxidative stress
Received: 8/12/13; Accepted: 8/31/13; Published: 9/4/13
Correspondence to: Luigi Fontana, MD/PhD; E‐mail: fontana@dom.wustl.edu
Copyright: © Soare et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract: Dietary supplements are widely used for health purposes. However, little is known about the metabolic and
cardiovascular effects of combinations of popular over‐the‐counter supplements, each of which has been shown to have
anti‐oxidant, anti‐inflammatory and pro‐longevity properties in cell culture or animal studies. This study was a 6‐month
randomized, single‐blind controlled trial, in which 56 non‐obese (BMI 21.0‐29.9 kg/m2) men and women, aged 38 to 55 yr,
were assigned to a dietary supplement (SUP) group or control (CON) group, with a 6‐month follow‐up. The SUP group took
10 dietary supplements each day (100 mg of resveratrol, a complex of 800 mg each of green, black, and white tea extract,
250 mg of pomegranate extract, 650 mg of quercetin, 500 mg of acetyl‐l‐carnitine, 600 mg of lipoic acid, 900 mg of
curcumin, 1 g of sesamin, 1.7 g of cinnamon bark extract, and 1.0 g fish oil). Both the SUP and CON groups took a daily
multivitamin/mineral supplement. The main outcome measures were arterial stiffness, endothelial function, biomarkers
of inflammation and oxidative stress, and cardiometabolic risk factors. Twenty‐four weeks of daily supplementation with
10 dietary supplements did not affect arterial stiffness or endothelial function in nonobese individuals. These compounds
also did not alter body fat measured by DEXA, blood pressure, plasma lipids, glucose, insulin, IGF‐1, and markers of
inflammation and oxidative stress. In summary, supplementation with a combination of popular dietary supplements has
no cardiovascular or metabolic effects in non‐obese relatively healthy individuals.

INTRODUCTION

Some individuals, especially heavy supplement users,
typically consume combinations of dietary supplements
because they believe that multiple compounds can act
through complimentary, additive or synergistic
mechanisms to convey a greater biologic effect than can
be achieved by any individual supplement [2]. The
present study was a randomized clinical trial to evaluate
the effectiveness of supplementation with a combination
of some of the most self-prescribed dietary supplements
(i.e. resveratrol, curcumin, green/black/white tea
extract, quercetin, acetyl-l-carnitine, lipoic acid,
pomegranate, cinnamon bark, sesamin, and fish oil), in

Non-vitamin, non-mineral dietary supplements are
widely used for health purposes and sometimes as a
substitute to a healthy diet or conventional medical
treatments. Nearly 1 in 7 adults takes supplements
regularly, and approximately 40% have taken one or
more dietary supplements during their life [1].
However, despite the widespread and growing use of
these over-the-counter products, insight into the
potential beneficial or harmful biological effects of
these compounds in humans is frequently lacking.
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lean and overweight middle-aged men and women
eating a Western diet. It has been reported that these
compounds exert powerful protective effects against
inflammation, oxidative stress/free radical damage,
insulin resistance, and protein glycation in cell culture
and laboratory animal studies [3-24]. We evaluated the
combined effects of these supplements on arterial
stiffness, endothelial function, markers of inflammation,
oxidative stress, glucose and lipid metabolism, and
blood pressure.

participants in the SUP group took all of the prescribed
doses of the supplements. All participants in both
groups
complied
with
the
vitamin/mineral
supplementation regimen.
There were no differences between groups in PWV, AI,
blood pressure, and endothelium-dependent and
endothelium-independent brachial artery vasodilation
(Table 1). No changes in body weight or % total body
fat occurred in either study group (Table 2). Plasma
lipid concentrations and indices of glucoregulation did
not change in either group (Table 2). No differences
between groups were observed for markers of
inflammation, oxidative stress and glycation, and blood
counts (Table 2).
Serum insulin and IGF-1
concentrations did not change in either group (Table 2).
Since completing the randomized trial, all but one of the
participants in the SUP group continued for another 6
months on the supplementation regimen. Even with this
longer, 12 month period of supplementation, no changes
in any outcome were observed (data not shown).

RESULTS
Study Participants
Screening, enrollment, and follow-up information is
presented in Fig. 1. The study participants were
generally healthy, as reflected by the following: BMI,
25.0±2.3 kg/m2; total cholesterol, 187±32 mg/dL;
triglycerides, 79±53 mg/dL; fasting glucose, 82±9
mg/dL; and systolic and diastolic blood pressures of
109±12 and 68±8 mmHg, respectively. The proportions
of men and women did not differ between groups
(p=0.65). The average age of participants was slightly
lower in the SUP group (means±SD: 44±6 vs. 47±5 yr,
p=0.05). BMI did not differ (p=0.65) between the SUP
(25.2±2.0 kg/m2) and control (24.9±2.5 kg/m2) groups.
Based on monthly pill compliance queries, 96% of the

No serious adverse events occurred. Serum markers of
liver and kidney function were unaffected by
supplementation. Other adverse events were limited to
mild gastrointestinal discomfort associated with taking
the large number of oral supplements in 19% of the
participants.

Figure1. Consort diagram reflecting flow of study participants through the study
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Table 1. Effect of 6 months of nutritional supplements or control on indices of arterial stiffness, vasomotor
function, and blood pressure.
Adjusted
Difference
Between
Groups

Between
Group
P value

5.2 ± 0.2
5.3 ± 0.2
0.1 ± 0.3

-0.3 ± 0.4

0.36

11.7 ± 2.6
12.5 ± 2.8
0.8 ± 1.1

12.3 ± 2.8
13.0 ± 2.3
0.7 ± 1.1

0.4 ± 1.5

0.77

Flow-mediated dilation, %
Baseline
6 months
Change

5.0 ± 0.5
4.5 ± 0.4
-0.5 ± 0.5

4.1 ± 0.4
4.4 ± 0.3
0.3 ± 0.3

-0.3 ± 0.5

0.54

GTN-mediated dilation, %
Baseline
6 months
Change

16.1 ± 1.3
14.2 ± 1.6
-1.9 ± 1.1

14.6 ± 1.2
13.3 ± 0.9
-1.3 ± 1.4

-0.2 ± 1.7

0.93

Systolic BP, mmHg
Baseline
6 months
Change

108 ± 2
108 ± 2
0±1

109 ± 2
107 ± 3
-2 ± 1

1±2

0.48

Diastolic BP, mmHg
Baseline
6 months
Change

69 ± 1
69 ± 1
0±1

66 ± 2
64 ± 2
-2 ± 1*

2±1

0.08

Supplements(n=
28)

Control
(n=26)

Pulse wave velocity, m/s
Baseline
6 months
Change

5.4 ± 0.3
4.8 ± 0.3
-0.5 ± 0.4

Augmentation index, %
Baseline
6 months
Change

Values are arithmetic means ± SE except for mean differences between groups, which have been adjusted for
baseline values. Between-group P values reflect the between-group comparison change-scores from
ANCOVAs that included baseline values as the covariate. *Significant (p≤0.05) within-group change. GTN,
nitroglycerine; BP, blood pressure. Several subjects in the supplement group (n=15) and control group (n=14)
did not undergo testing for GTN-mediated dilation because systolic blood pressure was below 100 mmHg,
which is a contraindication to GTN administration.

DISCUSSION

markers of inflammation, oxidative stress and glycation,
plasma lipids, growth factors, or body composition.

Our findings indicate that daily use of multiple dietary
supplements has no effect on arterial stiffness (i.e. pulse
wave velocity and augmentation index), endothelial
function (i.e. brachial artery flow-dependent
vasodilatation) or blood pressure in nonobese men and
women. Furthermore, supplementation with these
compounds did not affect key metabolic variables
implicated in the biology of aging, and in the
pathogenesis of cardiovascular disease, including plasma

www.impactaging.com

Reports from studies conducted mainly on cells in
culture or in experimental animals suggest that these
compounds promote metabolic health and may have
anti-aging effects [4-24]. In particular, resveratrol,
quercetin, curcumin, acetyl-L-carnitine, lipoic acid, fish
oil, sesamin, pomegranate, cinnamon bark, and green
tea extracts have all been reported to have powerful
anti-oxidant and/or anti-inflammatory properties [4-24].
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Table 2. Risk factors for cardiovascular disease and diabetes, and circulating markers of oxidative stress,
chronic inflammation, in response to 6 months of nutritional supplementation or control.
Adjusted
Between
Supplements
Control
Difference
Group
(n=28)
(n=26)
Between
P value
Groups
Body Mass and Composition
Body mass, kg
Baseline
6 months
Change

73.8 ± 2.3
74.2 ± 2.5
0.3 ± 0.4

72.8 ± 1.8
73.1 ± 1.7
0.2 ± 0.4

0.1 ± 0.6

0.91

30.1 ± 1.1
29.9 ± 1.0
-0.2 ± 0.3

30.2 ± 1.7
30.3 ± 1.8
0.2 ± 0.3

-0.2 ± 0.4

0.70

79 ± 12
75 ± 6
-4 ± 11

78 ± 8
87 ± 8
8±4

-12 ± 8

0.16

Total cholesterol, mg/dL
Baseline
6 months
Change

186 ± 6
186 ± 6
-1 ± 4

189 ± 6
192 ± 5
4±4

-5 ± 5

0.32

LDL-cholesterol, mg/dL
Baseline
6 months
Change

110 ± 6
111 ± 5
1±3

114 ± 6
115 ± 5
1±4

-1 ± 5

0.80

HDL-cholesterol, mg/dL
Baseline
6 months
Change

61 ± 3
59 ± 3
-2 ± 2

61 ± 3
60 ± 3
-1 ± 2

-1 ± 2

0.59

80 ± 2
83 ± 2
3±2

84 ± 2
85 ± 2
1±2

-1 ± 2

0.70

3.3 ± 0.3
3.6 ± 0.4
0.3 ± 0.3

2.8 ± 0.3
2.9 ± 0.3
0.1 ± 0.2

0.3 ± 0.4

0.41

0.64 ± 0.06
0.74 ± 0.09
0.10 ± 0.06

0.60 ± 0.06
0.63 ± 0.06
0.03 ± 0.04

0.08 ± 0.08

0.32

Body fat, %
Baseline
6 months
Change
Lipids
Triglycerides, mg/dL
Baseline
6 months
Change

Glucoregulatory Function
Fasting glucose, mg/dL
Baseline
6 months
Change
Fasting insulin, µU/mL
Baseline
6 months
Change
HOMA-IR
Baseline
6 months
Change
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Table 2 (continued). Risk factors for cardiovascular disease and diabetes, and circulating markers of oxidative
stress, chronic inflammation, in response to 6 months of nutritional supplementation or control.
Adjusted
Between
Supplements
Control
Difference
Group
(n=28)
(n=26)
Between
P value
Groups
Inflammatory Cytokines and Oxidative Stress Markers
CRP, mg/L
Baseline
1.69 ± 0.48
6 months
1.51 ± 0.20
Change
-0.17 ± 0.49

1.21 ± 0.52
1.44 ± 0.56
0.23 ± 0.10*

-0.20 ± 0.43

0.46

TNFα, pg/mL
Baseline
6 months
Change

1.92 ± 0.09
1.94 ± 0.09
0.02 ± 0.05

2.10 ± 0.18
2.13 ± 0.19
0.03 ± 0.14

-0.05 ± 0.14

0.70

IL-6, pg/mL
Baseline
6 months
Change

1.26 ± 0.26
1.35 ± 0.23
0.08 ± 0.08

1.39 ± 0.31
1.68 ± 0.32
0.29 ± 0.20

-0.22 ± 0.20

0.27

0.83 ± 0.03
0.76 ± 0.03
-0.07 ± 0.04

0.79 ± 0.03
0.82 ± 0.03
0.03 ± 0.03

-0.06 ± 0.04

0.14

307 ± 14
287 ± 12
-20 ± 13

272 ± 13
270 ± 12
-2 ± 12

1 ± 14

0.96

White Cell Counts and Growth Factors
WBC, k/cumm
Baseline
5.1 ± 0.2
6 months
5.0 ± 0.2
Change
-0.1 ± 0.2

4.8 ± 0.2
5.1 ± 0.3
0.3 ± 0.2

-0.3 ± 0.3

0.20

1.50 ± 0.05
1.42 ± 0.06
-0.08 ± 0.04*

1.42 ± 0.09
1.44 ± 0.10
0.02 ± 0.05

-0.10 ± 0.06

0.11

145 ± 6
151 ± 7
6±5

148 ± 7
144 ± 6
-4 ± 4

9±6

0.15

Protein carbonyl, nmol/mg
Baseline
6 months
Change
AGEs, ng/mL
Baseline
6 months
Change

Lymphocytes, k/cumm
Baseline
6 months
Change
IGF-1, ng/mL
Baseline
6 months
Change

Values are arithmetic means ± SE except for mean differences between groups which have been adjusted for
baseline values. Between-group P values reflect the between-group comparison change-scores from
ANCOVAs that included baseline values as the covariate. *Significant (p≤0.05) within-group change.
Triglyceride data were also adjusted for a significant effect of age on the baseline to follow up changes.
Within-group P values are from paired t-tests. LDL, low density lipoprotein; HDL, high density lipoprotein;
HOMA-IR, homeostasis model assessment of insulin resistance; CRP, C-reactive protein, TNFα, tumor
necrosis factor α; IL-6, interleukin-6; AGEs, advanced glycation end products; WBC, white blood cells; IGF-1,
insulin-like growth factor-1. To convert units to SI units, multiply the conventional units by the following
conversion factors: triglycerides x 0.0113 = mmol/L; total, LDL-, and HDL-cholesterol x 0.0259 = mmol/L;
glucose x 0.0555 = mmol/L; insulin x 6.945 = pmol/L.
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However, in our study we did not see any reduction in
markers of inflammation or oxidative stress. Oxidative
stress and inflammation are major players in the
pathogenesis of arterial aging and endothelial
dysfunction, which is a precursor of atherosclerosis [2529]. Nevertheless, pulse wave velocity, augmentation
index and endothelium-dependent vasorelaxation did
not improve in the supplement group. Furthermore,
supplementation with these compounds did not alter
other well-accepted cardiometabolic risk factors,
including blood pressure, insulin resistance, and serum
cholesterol, triglyceride and advanced glycation endproducts concentrations. Endothelial function can be
improved with just a single infusion of the anti-oxidant,
vitamin C [30]. Because all the supplements that we
used have been reported to have powerful antiinflammatory and anti-oxidant effects, it is interesting
that no biological change in endothelial function was
observed. In contrast, it has been shown that 6-mo or 1yr supplementation with DHEA-s results in significant
improvements of glucose tolerance, arterial stiffness
and inflammation [31].

resveratrol in wine, cathechins in green and black tea,
pomegranate in fruits, curcumin in spices, etc.).
Findings from the present study suggest that a
combination of several popular nutritional supplements,
which are commonly taken with the intention of
promoting healthy longevity and preventing chronic
disease, have no effects on arterial stiffness, endothelial
function, inflammation, oxidative stress, and other
chronic disease risk factors in non-obese men and
women. Additional randomized controlled studies are
still needed to assess the potential benefits of these and
other dietary supplements in obese metabolically
abnormal individuals.

METHODS
Participants. Non-obese (BMI 21.0-29.9 kg/m2) men
and women, aged 38-65y were recruited from the Saint
Louis area. Participants were free of chronic disease
based on a medical history, physical examination, blood
and urine chemistries, and electrocardiogram. Exclusion
criteria included chronic use of medications or dietary
supplements, tobacco use, alcohol abuse, and habitual
vigorous exercise. Participants consented to participate
in the study, which was approved by the Washington
University Institutional Review Board.

One possible explanation for the lack of beneficial
metabolic effects of these over-the counter dietary
supplements could be the low phytochemical
bioavailability or inadequate supplement potency of the
phytochemicals contained in some of these compounds
which are available without prescription [32].
Nonetheless, the fact remains that millions of
individuals in USA and Europe are consuming these
supplements, sometimes instead of a healthy diet and
conventional medical treatment, which might contain
hazard trace amounts of pesticides and heavy metals,
including lead, arsenic, mercury, and cadmium [1,33].
A placebo was not provided to control group
participants in the present study, which might be viewed
as a limitation. However, while a “placebo effect” might
have been an explanation for significant changes in the
supplement group, we did not observe changes.
Therefore, in this context, the lack of a placebo is not a
limitation. Moreover, although the sample size was
relatively small, there was no suggestion of clinically
significant differences from the between-group
estimates, despite multiple comparisons. Finally, it is
conceivable that some supplements might have had
beneficial effects that where counteracted by negative
effects of others. However, this seems unlikely and
people rarely take isolated supplements, and many of
these compounds are contained in foods and beverages
that are consumed regularly by millions of people.
Moreover, heavy supplement users believe that these
compounds work better in combination, because as with
food and beverages, they provide a mix of phytochemicals that interact and potentiate their effect (e.g.

www.impactaging.com

Study Design. The study was a 6-month single-blind
controlled trial in which participants were randomized
(1:1 ratio with stratification for sex) to a nutritional
supplement (SUP) group or control (CON) group. At
the end of the RCT, the participants who had been
randomized to SUP continued taking the supplements
for another 6-mo, while those who had been in the CON
group crossed over to the supplementation regimen for
6-mo. Technicians who performed outcomes
assessments were blinded to study group assignments.
Participants fasted overnight (12-hr) and refrained from
exercise for 24-hr before testing. For follow-up tests,
participants in the SUP group were instructed to take
their nutritional supplements upon waking in the
morning prior to testing. The primary outcome, carotidfemoral pulse wave velocity (PWV), was measured by
using Doppler flow measures. Another index of arterial
stiffness, carotid artery augmentation index (AI) was
measured using applanation tonometry. Endotheliumdependent and endothelium-independent brachial artery
vasodilation were evaluated by using ultrasound
imaging to measure flow-mediated dilation and glyceryl
trinitrate- (GTN)-mediated dilation, respectively.
Intervention. Participants in the SUP group took the
following dietary supplements: resveratrol (100
mg/day), quercetin (650 mg/day), acetyl-l-carnitine
HCL (500/mg/day), alpha-lipoic acid (600 mg/day),
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curcumin complex (900 mg/day; standardized to 95%
total curcuminoids, plus piperine 5 mg), pomegranate
extract (250 mg/day; standardized to 70% ellagic acid),
fish oil (1 g/day, containing 300 mg of eicosapentaenoic
acid and 200 mg docosahexaenoic acid), cinnamon bark
(1.7 g/day), green/white/black tea complex (800 mg/day
each of green, black, and white tea extract) and sesamin
(1 g/day; standardized to 500 mg sesamin lignans).
Sesamin was formulated by Scivation, Inc. (Burlington,
NC, USA) and all others by Swanson Health Products
(Fargo, ND, USA). Both groups received a daily
multivitamin/mineral supplement (Daily Multi-Vitamin
& Mineral, Swanson, Fargo, ND, USA) and were
advised to maintain their usual diet and physical
activity. Participants met with a member of the research
team each month to receive supplements and to answer
questions about compliance with the supplementation
regimen, changes in diet, physical activity, medical
conditions, and medication use, and adverse events.

measured by a CLIA-certified clinical laboratory at the
medical center.
Indices of arterial stiffness. Carotid artery augmentation
index (AI) was measured by using applanation
tonometry according to published guidelines [34].
Twenty digital pulse waves were recorded with a
tonometer (Millar Instruments, Inc., Model #TCB-500,
Houston, TX) and analyzed with Windaq software
(version 2.31, DATAQ Instruments, Inc., Akron, OH).
The the maximum and minimum voltage on each wave
form was identified and used to calculate pulse pressure
(PP). The second derivative of the pulse wave was
generated and used to identify the “shoulder” on the
upstroke of the raw wave form. Augmentation pressure
(AP) was calculated as the difference between the peak
voltage and the voltage at the shoulder. Augmentation
index was calculated as AI = 100 × AP/PP for each of
the 20 waveforms; the resulting values were averaged.
Because AI is dependent on heart rate, AI values were
adjusted to a standardized heart rate of 75 beats/min
based on the inverse relationship of 4.8 AI units per 10
beats/min HR [35]. The technician visually inspected all
waveforms to ensure that the landmarks had been
properly identified and to omit waveforms that were of
suboptimal quality due to artifacts or irregular
heartbeats. When analyses were questionable (e.g. large
variation in AI values among waveforms), the
waveforms were re-analyzed by another technician. If
discrepancies between the analyses occurred, the
technicians reviewed the analyses together and if the
differences could not be remediated, the data were
excluded.

Body weight and composition. Weight and height were
measured with a calibrated balance beam scale and
wall-mounted stadiometer, respectively, with the
participant wearing only a hospital gown and
underwear. BMI was calculated (kg/m2). Body
composition was evaluated using dual energy X-ray
absorptiometry (Delphi W, software version 11.2,
Hologic Corp., Waltham, MA). Bilateral brachial artery
blood pressure was measured with a calibrated monitor
(Dinamap 1846 SX, Critkon, Inc, Tampa, FL) according
to JNC 7 guidelines.
Circulating biomarkers of disease risk and aging. Blood
samples were collected from a forearm vein into
separate tubes containing sodium heparin, EDTA, and
no additives. Plasma and serum were isolated by
centrifugation (3500 g, 15 min, 4º C) and stored at -80º
C for later batch analyses. Samples were analyzed for
plasma concentrations of glucose (glucose oxidase
method, 2300 Stat Plus, YSI Inc., Yellow Springs, OH)
and insulin (chemiluminescence assay, Immulite 1000,
Siemens USA, Malvern, PA). The homeostasis model
assessment of insulin resistance (HOMA-IR) was
calculated from fasting glucose and insulin. ELISA
assay kits were used to measure serum concentrations of
inflammatory cytokines (tumor necrosis factor α
(TNFα), interleukin-6 (IL-6), C-reactive protein (CRP),
Quantikine, R&D Systems, Minneapolis, MN),
oxidative stress markers (protein carbonyls (Cell
Biolabs, San Diego, CA) and advanced glycation endproduct (AGE) N-1-carboxymethyl lysine (MBL
International, Woburn, MA)), and insulin-like growth
factor-1 (IGF-1, Diagnostic Systems Laboratories,
Webster, TX). Plasma lipids and blood counts were
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Pulse wave velocity (PWV) was determined according
to standard procedures1 by using transcutaneous
Doppler flow measurements (Model 806-CB, Parks
Medical Electronics, Inc., Aloha, OR) at the right
common carotid artery and the right femoral artery.
Twenty Doppler wave forms were simultaneously
recorded (Windaq software, version 2.31, DATAQ
Instruments, Inc., Akron, OH) at the two sites. Pulse
transit time was determined as the difference in pulse
arrival times (based on the “foot” of the pulse wave, as
determined from the second derivative of the pulse
wave) for the carotid and femoral sites. Pulse transit
distances between the aorta and the carotid site and the
aorta and the femoral site were measured over the skin
using the second intercostal space as a landmark for the
aorta, with the difference between these distances being
considered the pulse propagation distance [36]. PWV
was calculated for each of the 20 pulses as the quotient
of the propagation distance (in meters) and transit time
(in seconds) and the 20 values were averaged. Quality
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control procedures were identical to those described
above for the AI method.

the intervention and no-treatment control groups was
1:1. Results indicate that 21 subjects per group would
be sufficient for detecting a 3.1 m/sec improvement in
pulse wave velocity, 27 subjects per groups would be
sufficient for detecting a 0.86 ng/mL reduction in IL-6,
and 12 subjects per groups would be sufficient for
detecting a 1.60 mg/L reduction in CRP. Therefore, our
proposed sample size of 56 participants (28 per group)
was sufficient to detect biologically relevant changes in
arterial stiffness and inflammation.

Vascular function. Brachial artery flow mediated
dilation (FMD) was used to measure endotheliumdependent vasodilation and glyceryl trinitrate- (GTN)mediated dilation was used to measure endotheliumindependent vasodilation. The participant’s right arm
was immobilized with the shoulder abducted at 70-90º
and elbow fully extended. Ultrasound images were
acquired using an ultrasound system (Agilent SONOS
5500, Andover, Massachusetts) equipped with an 11-3L
linear array transducer. The probe was secured using a
stereotactic clamp (Noga Engineering, Ltd.) to maintain
constant positioning over the artery throughout the
procedure. Ultrasound images were fed to a computer
for real time quantification of arterial diastolic diameter
(30 ± 2 measures/sec) using Vascular Imaging Analysis
software (VIA, version 9.60) [37]. Baseline diameter
was recorded for 2 minutes before a pneumatic cuff
(Hokanson E20 Rapid Cuff Inflator and AG101 Cuff
Inflator Air Source, PMS Instruments, Ltd.,
Maidenhead, UK) was inflated to 200 mmHg on the
right forearm to occlude blood flow. After 5 minutes of
occlusion, the pressure in the cuff was rapidly released
and arterial diameter was recorded continuously for 5
minutes. FMD was calculated as the percent increase in
diameter from baseline to peak diameter, where baseline
diameter was the average diastolic diameter over the 2minute baseline and peak diameter was recorded as the
10-second average of the highest diastolic diameter
after cuff deflation. After the FMD assessment, and
after the diameter of the artery returned to baseline, a
second 2-minute baseline data collection was
performed, followed by administration of 0.4 mg
sublingual GTN spray. Brachial artery diameter was
evaluated again 5 minutes after GTN administration.
GTN-mediated dilation was calculated as the percentage
increase in arterial diameter from baseline to 5 minutes
after GTN administration.

Power analyses were performed for PWV, IL-6, and
CRP to determine sample size. Respective results
indicated that sample sizes of 21, 27, and 12 subjects
per group would be adequate for detecting significant
effects. Therefore, 28 subjects per group was chosen.
Baseline characteristics were compared with
independent t-tests and chi-square tests. Outcomes were
analyzed with analysis of covariance, in which baseline
values were included as a covariate. Paired t-tests were
used for within-group paired comparisons. Significance
was accepted at p≤0.05 and tests were two-tailed.
Analyses were conducted with SAS for Windows XP
Pro (version 9.3, SAS Institute, Cary, NC).
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